Showing results (271-280 of 353) with videos related to
Sort By:
Pageof 36
Blood|January 12, 2012
Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL DatabaseAnn S LaCasce, Jonathan L Vandergrift, Maria A Rodriguez, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2013
A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomabOliver W Press, Joseph M Unger, Lisa M Rimsza, et al.British Journal of Haematology|October 12, 2013
Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes databaseMakiko Ban-Hoefen, Ann Vanderplas, Allison L Crosby-Thompson, et al.Cancer|April 8, 2014
Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer NetworkAlex F Herrera, Allison Crosby-Thompson, Jonathan W Friedberg, et al.The New England Journal of Medicine|June 22, 2017
Implementation of Medical Homes in Federally Qualified Health CentersJustin W Timbie, Claude M Setodji, Amii Kress, et al.Health Affairs (Project Hope)|March 8, 2017
Synthesis Of Research On Patient-Centered Medical Homes Brings Systematic Differences Into ReliefAnna D Sinaiko, Mary Beth Landrum, David J Meyers, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2018
Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus <sup>131</sup>I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016Mazyar Shadman, Hongli Li, Lisa Rimsza, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016Oliver W Press, Joseph M Unger, Lisa M Rimsza, et al.Blood|December 8, 2009
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemiaJonathan W Friedberg, Jeff Sharman, John Sweetenham, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2015
Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108Paul M Barr, Hongli Li, Catherine Spier, et al.Pageof 36